Categories
Banking and Restructuring Controlled Substance Act Legislation Mergers and Acquisitions Regulatory Compliance

Distressed Cannabis Sale-Leaseback Companies: What Investors and Operators Need to Know

Marc A. Polito —

The cannabis industry has experienced dramatic highs and lows over the past several years. While legalization efforts have expanded markets across the United States, many cannabis companies have found themselves in severe financial distress, burdened by high operating costs, regulatory complexity, and limited access to traditional financing. One area that has drawn particular attention is the sale-leaseback model—a once-promising financing structure that has become a source of significant stress for both operators and the real estate companies and equipment lessors that serve them. Here’s a breakdown of the top four things to know about the use of sale-leasebacks in the cannabis industry.

1. Understanding the Real Estate Sale-Leaseback Model in Cannabis

A sale-leaseback transaction involves a cannabis operator selling its real property—such as a cultivation facility or dispensary location—to a third party or affiliate real estate investment company, then leasing that same property back under a long-term lease agreement. For the operator, this arrangement frees up capital that would otherwise be locked in real estate, providing much-needed liquidity to fund operations, expansion, or debt repayment. For the buyer, typically a real estate investment trust or similar entity, the arrangement provides a steady stream of rental income backed by a tangible asset.

This model gained traction in the cannabis space largely because of federal illegality under the Controlled Substances Act, which left cannabis companies cut off from conventional bank lending and capital markets.

Sale-leasebacks offered a creative workaround, enabling operators to monetize their real estate holdings without relying on traditional debt instruments.

2. Equipment Sale-Leasebacks: A Parallel Structure

While real estate sale-leasebacks have received much of the attention, equipment sale-leasebacks have played an equally important role in cannabis financing. Under this structure, a cannabis operator sells specialized equipment—such as extraction machines, HVAC systems, lighting arrays, or processing machinery—to a third party or affiliate financing company, then leases that equipment back for continued use. Like its real estate counterpart, the equipment sale-leaseback provides operators with immediate liquidity while allowing them to retain operational use of critical assets.

However, equipment sale-leasebacks carry their own distinct risks. Cannabis equipment is often highly specialized, meaning its residual value outside the cannabis industry can be minimal. If an operator defaults on its lease payments, the financing company may be left holding equipment that is difficult to redeploy or resell at a reasonable price. Additionally, equipment depreciates far more rapidly than real estate, which can create a mismatch between the outstanding lease obligations and the declining value of the underlying asset. These dynamics have left many equipment leaseback companies in a precarious financial position as operator defaults have increased across the industry.

3. Why Distress Has Emerged

Despite initial optimism, several factors have converged to place sale-leaseback companies under significant financial pressure.

  • First, cannabis commodity prices have declined sharply in many mature markets, driven by oversupply and aggressive competition. As operator revenues have fallen, many lessees have struggled to meet their lease obligations, leading to rising delinquencies and defaults across both real estate and equipment leases.
  • Second, the real estate and equipment financing companies themselves often underwrote these transactions based on optimistic projections about the cannabis market’s growth trajectory. When those projections failed to materialize, the underlying economics of many deals became unsustainable. For example, real estate properties that are acquired at premium valuations tied to cannabis use can be difficult to repurpose for other commercial uses whether due to current outfitting of the location or as a result of local zoning laws, and specialized equipment can hold even less residual value outside the cannabis industry, leaving both landlord and lessors with impaired assets and limited options.
  • Third, the broader macroeconomic environment has compounded these challenges. Rising interest rates have increased the cost of capital for real estate companies and equipment lessors, while simultaneously depressing asset valuations. For sale-leaseback companies that relied on leverage to fund acquisitions of real estate and equipment, this has created a painful squeeze on balance sheets. What we have seen is a trend toward sale-leaseback companies defaulting under their own debt obligations used to finance the acquisition of real estate and equipment due to their underlying portfolio tenants and lessees defaulting under respective lease agreements.

4. Implications for Stakeholders and Operators

For cannabis operators, the distress of their sale-leaseback landlords can create its own set of complications. A landlord in financial difficulty may be unable to fund required maintenance or capital improvements under the leases, and as a result, may seek to renegotiate lease terms, or may face foreclosure proceedings that introduce uncertainty into the operator’s occupancy rights.

For investors and creditors of sale-leaseback companies, the path forward often involves difficult decisions around restructuring, asset disposition, or recapitalization. In some cases, distressed sale-leaseback portfolios have attracted opportunistic buyers looking to acquire cannabis-linked real estate at a discount.

The distressed cannabis sale-leaseback space serves as a cautionary tale about the risks of sector-specific financing models built on speculative market assumptions. As the industry continues to mature, stakeholders would be well served by approaching these structures with clear-eyed diligence and realistic expectations about the market’s trajectory.

Categories
Banking and Restructuring Controlled Substance Act Interviews Legislation Meet Blank Rome Mergers and Acquisitions Regulatory Compliance

Cannabis Rescheduling: Will the Vault for Cannabis Banking and Financial Services Finally Be Opened?

Scott H. Moskol and Lauren Medeiros Forster —

Whether you are a cannabis operator, lender, or investor, you have probably been hearing a lot of buzz about the potential rescheduling of cannabis from Schedule I to Schedule III under the federal Controlled Substances Act, especially following President Trump’s recent executive order directing federal agencies to initiate the process of rescheduling marijuana and reviewing related regulations. It is an exciting development, and there is plenty of reason for optimism, but let’s take a look at what this shift could change (and likely not change) when it comes to banking, lending, and financial services in cannabis.

  1. The Banking Landscape: Evolution, Not Revolution

It is likely that rescheduling cannabis to Schedule III will not dramatically change what banks are presently required to do under the Bank Secrecy Act (the “BSA”) and the 2014  FinCEN guidance on banking marijuana-related businesses. These BSA-related compliance obligations (i.e., the enhanced due diligence, suspicious activity reporting, and monitoring requirements) will not vanish as a result of rescheduling. Banks will still need to navigate a complex regulatory and compliance environment, and if you are a financial institution already working with cannabis operators or you are a cannabis business already working with a financial institution, your day-to-day relationship will not change.

What the industry is hoping for, however, is that rescheduling will prompt federal regulators to issue amended or entirely new guidance on how banks can engage with the cannabis industry. That kind of updated regulatory framework could open doors to more streamlined processes and potentially reduce some of the friction that has defined cannabis banking for years but more importantly bring in new financial institutions providing banking and lending services to the industry. Eyes should be kept on Treasury and the banking regulators—their next moves will matter once cannabis is rescheduled.

Categories
Controlled Substance Act Legislation Meet Blank Rome Regulatory Compliance

2025 Wrap-Up: Historic Cannabis Rescheduling

Blank Rome’s Cannabis Practice Applauds Milestone EO and Anticipates Continued Developments and Opportunities in 2026

Frank A. Segall and Shane A. Pennington 

President Trump recently signed Executive Order “Increasing Medical Marijuana and Cannabidiol Research,” published on December 18, 2025. This important measure directed federal agencies to reclassify cannabis from Schedule 1 to Schedule 3 under federal law, marking a major step forward for medical research, patient access, and the broader cannabis industry.

In recognition of this milestone, we would also like to acknowledge entrepreneur and philanthropist, Howard Kessler, for his visionary leadership and commitment to expanding medical cannabis access for seniors through The Commonwealth Project, which aligns with this significant occasion.

“We congratulate Howard Kessler on his vision, perseverance, and critical involvement in advancing medical cannabis access for senior healthcare through The Commonwealth Project, which resulted in President Trump’s historic Executive Order rescheduling cannabis from Schedule 1 to Schedule 3. Howard Kessler championed a cause and became its champion,” said Frank A. Segall, partner and co-chair of the Cannabis practice.

Following this Executive Order, Blank Rome’s Cannabis team has been actively engaging with the media, providing insights and analysis on the implications of rescheduling cannabis.

Categories
Controlled Substance Act Legislation Meet Blank Rome Regulatory Compliance

Blank Rome Poised to Guide Clients Through Marijuana Rescheduling

Shane A. Pennington, Frank A. Segalland Scott H. Moskol

As the cannabis industry anticipates a significant executive order that could reschedule marijuana from Schedule I to Schedule III, Blank Rome’s Cannabis industry group is ready to guide clients with strategic insight and timely advice. Regulatory authority and Blank Rome partner Shane A. Pennington, with the support of Cannabis industry group co-chairs Frank A. Segall and Scott H. Moskol, have been directly involved in addressing the Department of Justice’s proposal for rescheduling marijuana on behalf of our clients. Encouraging updates continue to emerge daily, and we believe an executive order authorizing this change will be issued soon.

Shane, Frank, Scott, and Blank Rome’s team of cannabis attorneys are at the cutting edge of industry trends, closely following and influencing policy developments in Washington, D.C. The Cannabis industry group is dedicated to keeping our clients updated in real time, helping you act swiftly and take advantage of new possibilities arising from this historic development.

Once a clear path is set by executive order, our team will host a series of meetings and webinars to help clients navigate the evolving regulatory landscape and maximize the benefits of rescheduling. Building on our longstanding leadership at the forefront of the cannabis industry, our deep knowledge of legal and regulatory issues enables us to guide clients through emerging changes, so they can confidently navigate and benefit from the evolving market.

As you prepare for this transformative moment in the industry, trust Blank Rome to be your partner every step of the way. For questions or to learn more about our services, please contact us.

Categories
Banking and Restructuring Controlled Substance Act Employment Issues ESOPs (Employee Stock Ownership Plans) Legislation Mergers and Acquisitions Regulatory Compliance

High Stakes and Material Changes in the Bay State: Senate Bill No. 2722 vs. House Bill No. 4160

Lauren Medeiros Forster —

There were several material changes relating to strategy, compliance, and deal‑making advanced by Massachusetts Senate Bill No. 2722 (“S. 2722”) on November 13, 2025. Below is a short summary of what you need to know about the Senate’s rewrite and meaningful reshaping of several House‑backed ideas (under House Bill No. 4160 (“H. 4160”)) for changing the legal regime of cannabis in the Commonwealth.

1.      Employee Stock Ownership Plans

Employee stock ownership plans (“ESOPs”) are here to stay. Both bills tell the Massachusetts Cannabis Control Commission (“CCC”) to set up clear procedures to allow the sale of a business to employees via an ESOP and to exclude a trustee acting solely for an ESOP during or after a sale when counting toward cannabis license caps under the Massachusetts cannabis laws. That part did not change, which is a positive result for the Commonwealth. The proposed changes to the current law enable succession planning, retention, and worker‑ownership options for operators and investors without tripping license caps and also improve exit/liquidity paths for owners. This also means there would be no caps on the number of licenses an ESOP can own.

Categories
Banking and Restructuring Controlled Substance Act Interviews Legislation Meet Blank Rome Mergers and Acquisitions Regulatory Compliance

Closing the Hemp Loophole: What Monday’s Farm Bill Update Means for Delta-8 and Hemp-Derived THC

Marc A. Polito —

At Blank Rome’s 9th Annual State of the Cannabis Industry Conference, Frank A. Segall, partner and co-chair of the firm’s Cannabis practice, asked a panel—including Joseph Andreae, CEO of CULTA, Jared Maloof, CEO of Standard Wellness, Ed Schmults, CEO of Firelands Scientific, and Jim Scott, CEO of Statehouse Holdings—what is the number one issue confronting the cannabis industry today? All four chief executives unanimously echoed the same sentiment: the number one issue confronting state-regulated cannabis operators today is the unregulated hemp market, which has become a growing thorn in their sides as the hemp market picked up steam over the past few years. Well, with new action by lawmakers yesterday, it appears this issue is on the brink of being resolved!

Over the past six years, the hemp industry has transformed from a niche agricultural sector into a national marketplace for diverse cannabinoid products. That transformation was catalyzed by the 2018 Farm Bill, which legalized hemp by defining it as cannabis with no more than 0.3 percent delta-9 tetrahydrocannabinol (“THC”) on a dry-weight basis. What resulted from this was an unintended market: intoxicating hemp-derived cannabinoids such as delta-8 THC, delta-10 THC, and other analogs produced from cannabidiol (“CBD”) isolates through chemical conversion. The “hemp loophole,” as it came to be known, allowed psychoactive products to proliferate in convenience stores, restaurants, and online and circumvented the strict controls applied to state-licensed cannabis.

Categories
Controlled Substance Act Legislation Meet Blank Rome Regulatory Compliance

Federal Marijuana Rescheduling Effort Challenged in Congress

Marc A. Polito —

Where Things Stand Now

Last week, Republican lawmakers in Congress took a major step to block President Donald Trump’s potential move to reschedule marijuana. The GOP-controlled House Appropriations Committee approved a spending bill that would prohibit the Department of Justice (the “DOJ”) from using federal funds to reschedule or deschedule marijuana under the Controlled Substances Act. This move comes as the Trump administration signals it is considering reclassifying cannabis from Schedule I to Schedule III, a change that would have significant implications for the industry and for federal-state relations.

The bill, advanced by the House Appropriations Committee, includes explicit language: “None of the funds appropriated or otherwise made available by this Act may be used to reschedule marijuana… or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act.” This provision, if enacted, would effectively freeze the ongoing federal review process and reserve the authority to change marijuana’s status exclusively for Congress, rather than the executive branch.

Categories
Banking and Restructuring Controlled Substance Act Employment Issues Legislation Meet Blank Rome Mergers and Acquisitions Regulatory Compliance

Turning Over a New Leaf: How Cannabis Receiverships Can Cultivate a Stronger Future

Lauren Medeiros Forster —

It is no secret that the cannabis industry has been on a wild ride lately, especially in mature markets. Many operators are feeling the pressure, and they are not alone. Let us break down the current landscape, why it is tough out there, and how receiverships and distressed sales might actually be a positive move for struggling cannabis companies.

Many developed cannabis markets are facing serious challenges. Inflation and a shaky economy are making it harder for businesses to stay afloat (regardless of industry type), on top of market saturation that has caused cannabis prices to drop, and tight profit margins for businesses in the more established marijuana states. This is compounded with the harsh effects of tax burdens due to 280E—where cannabis companies are unable to deduct otherwise established business expenses from gross income as a result of the federal illegality of cannabis in the United States—and lack of liquidity from inability to access traditional debt financing and institutional equity markets. As a result, many cannabis companies are finding it difficult to pay their debts and keep the lights on. And because cannabis is still federally illegal in the United States, struggling cannabis operators are limited when it comes to utilizing federal bankruptcy mechanisms for relief.

But hope is not lost. Even in tough times, cannabis businesses along with their management, creditors, and investors, have found options to help their companies restructure and move forward. One of those is a state-level receivership.

Categories
Controlled Substance Act

Hold Your Horses – Cannabis Rescheduling Hearings Stayed, Pending Appeal

In the latest development in a road to rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act (“CSA”), on January 13, 2025, in the Matter of Schedules of Controlled Substances: Proposed Rescheduling of Marijuana, DEA Docket No. 1362 Hearing Docket No. 24-44, Chief Administrative Law Judge (“ALJ”) John Mulrooney cancelled the January 21, 2025 hearing on the merits of the Drug Enforcement Agency’s (“DEA”) proposal to reschedule cannabis from Schedule I to Schedule III.

After a request by two private movants (the “Movants”) to remove the DEA from its role as proponent of the proposed reclassification rule was denied, the Movants filed a motion for the ALJ to reconsider its denial of this request. On January 13, 2025, ALJ Mulrooney (i) denied the motion for reconsideration but (ii) granted leave for the Movants to file an interlocutory appeal on the merits of ALJ Mulrooney’s refusal to remove the DEA as proponent of the reclassification. While this Order opens the door on appeal to potentially enable to a private actor to replace the DEA as proponent of the reclassification, the January 13 Order will surely cause further delay in the process of potential rescheduling, evidenced by ALJ Mulrooney’s ordering the Movants and the Government to provide a joint status update 90 days from the issuance of the Order, and every 90 days thereafter.

For those hoping that cannabis would be reclassified before the Trump administration enters office, this is a major disappointment. For those who have been paying attention, this is no surprise, and more of the same.

In a constantly evolving and [still – very] nascent industry like the cannabis industry, one truth has remained: it is a fools errand to try to predict if, when, and how regulatory changes and developments will occur at the federal level. For years, there have been similar questions floated and discussed amongst advisors, operators, and investors in the cannabis industry: “when will cannabis be legalized?”,“when will the SAFE act pass”, “surely Congress will do something, right?”.

Federal action is largely an issue of legislative and regulatory priorities (or, as we have seen, a lack-thereof). Folks can talk and pontificate all they want, but the reality has remained the same: States (at this point, 39 in total, having already passed laws allowing medical marijuana use) are left to fend for themselves, as are the businesses trying to operate with one (if not two) arms tied behind their back.

When President Biden requested in October 2022 for the U.S. Department of Health and Human Services (“HHS”) to “initiate the administrative process to review expeditiously how marijuana is scheduled under federal law”, there was tepid excitement. Hey – the White House is asking HHS to look into this… progress! Then, in August 2023, HHS issued a recommendation to the DEA that cannabis be reclassified from Schedule I to Schedule III under the CSA. At this point, industry participants started to cautiously buy in – maybe – just maybe – this will be the time something actually happens. After all, for business operators, a reclassification to Schedule III under the CSA, would have potentially huge implications – potentially rendering §280E of the tax code inapplicable to cannabis businesses, opening the door for cannabis businesses to deduct various business expenses like any other businesses complying with their state and local laws. And yet, here we are, almost two and a half years later, and the industry is still hoping for change at the federal level.

For operators and investors alike, the reality is simple. Now is not the time to focus on what could happen – or what we hope will happen – at the federal level. Industry participants must continue to focus on what they control: increasing operational efficiency to achieve and maintain profitability.

Categories
Controlled Substance Act Employment Issues Legislation Meet Blank Rome Mergers and Acquisitions Regulatory Compliance

Welcome to Cannabis Industry Insights

Frank A. Segall, Scott H. Moskol, and Max M. Borg —

Whether you are a plant-touching operator or an ancillary business, lender, or investor, Blank Rome’s Cannabis Industry Insights blog is your go-to resource for the cannabis industry.

Authored by our trailblazing Cannabis practice attorneys, the Cannabis Industry Insights blog explores the rapidly evolving legal, regulatory, and business landscape, helping those in the sector stay ahead of the curve and seize industry opportunities. Our cannabis team was one of the first in the United States to utilize its extensive corporate and finance experience to support the cannabis industry, and has received numerous accolades, including Law360’s prestigious 2023 Cannabis Practice Group of the Year.

Through our blog, we will continue to explore issues that directly impact the cannabis industry. With the announcement of the rescheduling of cannabis from Schedule 1 to Schedule 3 under the Controlled Substance Act, we are optimistic about new and expanding opportunities for industry players. In addition to interviews with industry leaders, the blog will cover such topics as the impact of rescheduling on 280E taxation; legal and regulatory compliance concerns; the landscape for mergers and acquisitions; legislative efforts; banking, insurance, and other business issues; capital markets; workouts and restructurings impacting the industry; the growing importance of e-commerce, fintech, and regtech; debt and equity financings; labor and employment issues in light of unionization efforts; data privacy and security; and employee stock ownership plans (“ESOPs”); among other areas that are relevant to the underpinnings of the industry.

Our goal is to help cannabis businesses survive and thrive in this highly regulated environment, as well as to assist new participants in entering this exciting industry. Subscribe below to receive our timely content: